退市边缘的青海春天：虫草应收款七千万，酒水销售终端数据成谜

Core Viewpoint - Qinghai Spring is on the verge of delisting from the A-share market, transitioning from a peak as the "first stock of Cordyceps" to being labeled as *ST Spring, with significant concerns regarding its financial health and core business operations [1] Group 1: Financial Performance and Risks - For the first three quarters of 2025, Qinghai Spring reported a main business revenue of approximately 209 million yuan, with specific revenues from liquor at 87.68 million yuan, traditional Chinese medicine at 36.26 million yuan, and Cordyceps sales at 84.99 million yuan [2] - The company has adopted a credit sales strategy, leading to a significant accounts receivable of 67.89 million yuan for Cordyceps sales, raising concerns about the potential inability to recognize some sales revenue [2][4] - The company has not received terminal sales data from liquor distributors, which may affect revenue recognition, echoing previous concerns from the 2024 annual report regarding unrecognized revenue of 68.11 million yuan due to inventory and return risks [2] Group 2: Prepayment Issues - Qinghai Spring has over 100 million yuan in prepayments to Yibin Tinghua Wine Trading Co., with 140.18 million yuan outstanding as of September 30, 2025, raising regulatory concerns [3][4] - The company plans to reduce the prepayment balance to around 100 million yuan by the end of the year and align it with procurement scales by mid-2026 [4] - There is a risk of impairment for the prepayments due to potential delays in repayment from Yibin Tinghua, which could also impact the company's liquor sales business [4] Group 3: Delisting Risk - The company faces delisting risk as its audited profit totals for 2024 may fall below the thresholds set by the Shanghai Stock Exchange, with a warning that its stock could be suspended if financial metrics do not improve [5]